Publications for Josefine Bostner
Co-author map based on ISI articles 2007-

Publications mentioned in social media 9 times*

Keywords

tumors treatments tamoxifen s6k2 s6k1 resistance receptor protein patients pak1 kinase gene estrogen endocrine cells cancer breast amplification 4ebp1 11q13

Journal Articles

Helena Aguilar, Ander Urruticoechea, Pasi Halonen, Kazuma Kiyotani, Taisei Mushiroda, Xavier Barril, Jordi Serra-Musach, Abul Islam, Livia Caizzi, Luciano Di Croce, Ekaterina Nevedomskaya, Wilbert Zwart, Josefine Bostner, Elin Karlsson, Gizeh Perez-Tenorio, Tommy Fornander, Dennis C Sgroi, Rafael Garcia-Mata, Maurice Phm Jansen, Nadia García, Núria Bonifaci, Fina Climent, María Teresa Soler, Alejo Rodríguez-Vida, Miguel Gil, Joan Brunet, Griselda Martrat, Laia Gómez-Baldó, Ana I Extremera, Agnes Figueras, Josep Balart, Robert Clarke, Kerry L Burnstein, Kathryn E Carlson, John A Katzenellenbogen, Miguel Vizoso, Manel Esteller, Alberto Villanueva, Ana B Rodríguez-Peña, Xosé R Bustelo, Yusuke Nakamura, Hitoshi Zembutsu, Olle Stål, Roderick L Beijersbergen and Miguel Angel Pujana
  VAV3 mediates resistance to breast cancer endocrine therapy
 
Altmetric usage: 6

  Breast Cancer Research, 2014, 16(3), R53.
   Fulltext  PDF  
 Web of Science® Times Cited: 2

Elin Karlsson, Gizeh Pérez-Tenorio, Risul Amin, Josefine Bostner, Lambert Skoog, Tommy Fornander, Dennis C Sgroi, Bo Nordenskjöld, Anna-Lotta Hallbeck and Olle Stål
  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
 
Altmetric usage: 2

  Breast Cancer Research, 2013, 15(5), R96.
   Fulltext  PDF  
 Web of Science® Times Cited: 7

Josefine Bostner, Elin Karlsson, Muneeswaran J. Pandiyan, Hanna Westman, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
  Breast Cancer Research and Treatment, 2013, 137(2), 397-406.
 Web of Science® Times Cited: 17

Elin Karlsson, Marie Ahnström, Josefine Bostner, Gizeh Perez-Tenorio, Birgit Olsson, Anna-Lotta Hallbeck and Olle Stål
  High-Resolution Genomic Analysis of the 11q13 Amplicon in Breast Cancers Identifies Synergy with 8p12 Amplification, Involving the mTOR Targets S6K2 and 4EBP1
 
Altmetric usage: 1

  Genes, Chromosomes and Cancer, 2011, 50(10), 775-787.
   Fulltext  PDF  
 Web of Science® Times Cited: 18

Josefine Bostner, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Estrogen Receptor-alpha Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
  Clinical Cancer Research, 2010, 16(5), 1624-1633.
   Fulltext  PDF  
 Web of Science® Times Cited: 23

Josefine Bostner, Marie Ahnström Waltersson, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stål
  Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
  Oncogene, 2007, 26(49), 6997-7005.
 Web of Science® Times Cited: 56

Conference Articles

Josefine Bostner, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stal
  Estrogen Receptor alpha Phosphorylation on Serine 305, p21-Activated Kinase 1 and Tamoxifen Response in Postmenopausal Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 596S-596S
  CANCER RESEARCH, 2009.


E Karlsson, M A Waltersson, Josefine Bostner, Gizeh Perez-Tenorio, Birgit Olsson, T Fornander and Olle Stål
  Comprehensive Genomic and Transcriptomic Analysis of the 11q13 Amplicon in Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 820S-821S
  CANCER RESEARCH, 2009.


Ph.D. Theses

Josefine Bostner
  The Akt/mTOR Pathway and Estrogen Receptor Phosphorylations: a crosstalk with potential to predict tamoxifen resistance in breast cancer
  2013.


  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.